KRAS and colorectal cancer: Indeed, treatment of KRAS-mutated colorectal cancer cells with SJ-C1044, a type IIa RAF inhibitor, resulted in the inhibition of MEK and ERK activity in a concentration-dependent manner, without any evidence of paradoxical activation (Figure 2A).